Abbott Laboratories (ABT) is back in focus after presenting new multi-biomarker data for its Cancerguard multi cancer early ...

Abbott Laboratories (NYSE:ABT) is included among the 10 Best Bear Market Stocks to Invest in Right Now. On April 22, Daiwa ...

Buy the dip on Abbott (ABT): diversified healthcare growth, Exact Sciences boost, strong dividend, and discounted ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

They offer investors very different value propositions.

Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said its nutrition unit continued to notch soft sales during the first quarter. The company, which sells ...

Robert Ford (Chairman, President & CEO) said Q1 results were “aligned with our expectations for the start of the year,” citing “adjusted earnings per share of $1.15, consistent with our guidance ...

Abbott Laboratories shares are down about 6% after the medical devices and nutrition company gave a 2026 forecast that disappointed analysts. In its first quarter report released Thursday, analysts fl ...

Abbott’s CancerGuard data and AACR recognition are strengthening its oncology diagnostics story and adding fresh depth to its ...

Abbott Laboratories stock has reached a 52-week low, trading at $100.85. This milestone marks a significant downturn for the $175.86 billion healthcare giant, reflecting a challenging year with a ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.